An Update on Management of Nonalcoholic Fatty Liver Disease & Nonalcoholic Steatohepapititis is the Time Ripe for Achieving Resolution of NAFLD & NASH Soon

Kulvinder Kochar Kaur (Dr Kulvinder Kaur Centre For Human Reproduction, Jalandhar, Punjab, 144001, India)
Gautam Allahbadia (Ex-Rotunda-A Centre for Human Reproduction, Mumbai, India)
Mandeep Singh (Swami Satyanand Hospital, Jalandhar, Punjab, India)

Abstract


We earlier reviewed how obesity has assumed an endemic/pandemicproportions that has resulted in escalating incidence and prevalence ofassociated escalating worldwide incidence of Metabolic Syndrome (MetS)with non alcoholic fatty liver disease (NAFLD), that is correlated withenhanced morbidity. Later we tried to detail how probiotics, L-Carnitine(LC), Nicotinamide Ribose (NR) Combination, along with Apical SodiumDependent Bile Acids Transporter (ASBT) or Volixibat and Silybin,Vitamin D, Allyl Isothiocyanate (AITC), might aid in treating andunderstand the etiopathogenesis of NAFLD. The prevalence of NAFLDall over the world is approximately 25%, with that of non alcoholicsteatohepapititis (NASH), varying from 1.5%=6.45%. Particularly NASH,specifically the ones associated with fibrosis possess a greater chance ofgeneration of side effects that include progression to cirrhosis as well asliver-associated mortality. Despite an improvement was observed withvitamin E, Pioglitazone. liraglutide in histological appearance in liverrandomized controlled clinical trials (RCT), at present no drugs existsthat have received FDI approval for NASH. The aim of this review wasto update the newer drugs getting evaluated, undergoing phase 2-3 trials.Currently there are Obeticholic acid, elafibranor, cenicriviroc, resmetriom,in addition to aramchol, that are the five agents that are getting analysedin big, histology dependent phase 3 trials. Hopefully within another 2-4years, newer, efficacious drugs will be available for the therapy of NASH.Besides that a lot of phase 2 trials are continuing for different drugs.Further depending on outcomes of phase 2-3 trials, combination treatmentsare getting evaluated. For future therapeutic approaches would be madeup of variations in NASH phenotypes, besides personalized approachesbased on various NASH phenotypes in addition to response of every singlepatient. Further recently there were reports of utilization of curcumin withnonselective beta blocker for regression from cirrhosis (reviewed by us).Hopefully once there are approved therapies for NAFLD/NASH, we canwork in that direction.

Keywords


NAFLD;NASH;Drug treatments;Combination therapy;Fibrosis;Cirrhosis

Full Text:

PDF

References


[1] Kulvinder Kochar Kaur,Allahbadia GN,Singh M. A Mini Review on Development of Newer Therapies for Non Alcoholic Fatty Acid Liver Disease with Emphasis on Vitamin D and its Receptor and Allyl Isothiocyanate (AITC)”. Acta Scientific Nutritional Health 2019; 3(12) :1-5.

[2] Kulvinder Kochar Kaur,Allahbadia GN,Singh M. An Update on Further Progression of NAFLD, NASH with Prospective Therapies Like L-Carnitine (LC), Nicotinamide Ribose (NR) Combination, as well as Apical Sodium Dependent Bile Acids Transporter (ASBT) or Volixibat and Silybin as Alternatives. Int J Clin Med Cases. 2020 Jan;3(3):138. DOI: 10.31021/ijcmc.20203138-29/1/2020 jan 29.

[3] Kulvinder Kochar Kaur,Allahbadia GN,Singh M. Have Probiotics and Synbiotics passed the test of time to be implemented in management of obesity and related metabolic disorders-a comprehensive review. Adv Obes Weight Manag Control. 2019;9(1):21-28. DOI: 10.15406/aowmc.2019.09.00269.

[4] Kulvinder Kochar Kaur,Allahbadia GN,Singh M. Will Probiotics Provide the Answer for Therapy of Non-alcoholic Fatty Liver Disease (NAFLD)? – A Systematic Review. Biochem Physiol 2020;9: 257.

[5] Kulvinder Kochar Kaur,Allahbadia GN,Singh M.. Rosmarinic Acid-A New Hope for Liver Diseases Like Cirrhosis, Hepatocellular Carcinoma-NeedsTranslation to Humans”. EC Endocrinology and Metabolic Research 2019;4(6 ): 289-301.

[6] Kulvinder Kochar Kaur,Allahbadia GN,Singh M. How do we apply advances in knowledge of Hepatic Macrophages in treating Liver Diseases especially non alcoholic fatty liver disease( NAFLD), non alcoholic steatohepapititis( NASH), with the increasing incidence of Diabesity-A Systematic Review.EC Endocrinology and Metabolic Research published in2020.

[7] Kulvinder Kochar Kaur,Allahbadia GN,Singh M. Mechanisms that associate extension of Nonalcoholic fatty liver diseases(NAFLD) to NASH (Nonalcoholic steatohepatitis) and further progressing to cirrhosis and Hepatocellular carcinoma(HCC) in addition to few proposed biomarkers for poor prognosis.J Gynaecol 2021;1(16):1-18.

[8] Kulvinder Kochar Kaur,Allahbadia GN,Singh M. How can we optimize therapy of Non Alcoholic Fatty Acid Liver Disease-A Short Communication on role of Astragaloside IV and other prospective agents”. Clinical Research and Clinical Case Reports, 2021;1(3):1-4. DOI: http;//doi.org/04.2021/1.1013.

[9] Kulvinder Kochar Kaur,Allahbadia GN,Singh M. Paradoxical Additional Role of SGLT2 Inhibitors Beyond Glycosuria in Controlling Obesity, NAFLD Treatment, Pancreatic β Cell Protection Besides Therapy for Diabetes Mellitus, CVOT and Renoprotection-A Minireview”. Acta Scientific Gastrointestinal Disorders 4.7 (2021): 15-26.

[10] Younossi ZM, Koenig AB,Abdelatif D,Fazel Y, Henry L,WymenM. Global epidemiology of non alcoholic fatty liver diseasemeta-analystic assessment of Prevalence, incidence andoutcomes. Hepatology 2016; 64:73-84.

[11] Angulo P,Kleiner DE,Dam-Larsen S,Adams LA,Bjornsson ES,Charat charoenwithalya P, etal. Liver fibrosis,but no other histological features ,is associated with long term outcomes of patients with Non Alcoholic Fatty Acid Liver Disease. Gastroenterology 2015; 149:389-97.

[12] Sayiner M, Koenig AB, Henry L, Younossi ZM. epidemiology of non alcoholic fatty liver diseaseand non alcoholic steatohepapititis in adults.Clin Liver Dis 2016; 20:205-14.

[13] GBD 2015.Mortality and causes of death Collaborators. Global,regional ,and national life expectancy ,all cause mortality,and cause specific mortality for 249 causes of death,1980-2015:a systematic review for the Global burden of disease study 2015.Lancet 2016; 388:1459--544.

[14] Younossi ZM, Stepanova M, Rafiq N,Makhlouf H, YounoszaiZ,Agrawal R,Goodman Z.Pathologic criteria for non alcoholic steatohepapititis :interprotocol agreement and ability to predict liver-related Mortality. Hepatology 2011; 53:1874-82.

[15] Konerman MA,Jones JC,Harrison SA. Pharmacotherapy for NASH:current and emerging: J Hepatol 2018;68: 362-75.

[16] Cusi K,Orsak B,BrilF,Lomonaco R,Hecht J,Ortiz-Lopez C , etal .Long term treatment for patients with non alcoholic steatohepatitis and pre Diabetes or type2 Diabetesmellitus: a randomized controlled trial.Ann Int Med 2016;165(5):305-15.

[17] Armstrong MJ,Gaunt P,Aithal GP,Barton D,Hull D,Parker R, etal .LEAN trial team .Liraglutidesafety and efficacy in for patients with non alcoholic steatohepatitis(LEAN):a multicenter ,double blinded, a randomized,placebo- controlled phase 2 study. Lancet 2016; 387:679--90.

[18] Caldwell S. NASH therapy:omega 3 supplementation, Vitamin E, insulin sensitizers and statin drugs.Clin Mol Hepatol 2017;23: 103-8.

[19] Abner EL,Schmitt FA,Mendiondi MS,Marcum JL,Kryscio RJ. Vitamin E and all cause Mortality:a meta-analysis.Curr Aging Sci 2011; 4:158-70.

[20] Schurks M,Glynn RJ,Rist PM,Tzurio C,Kurth T.Effects of Vitamin E on stroke subtypes: meta-analysis of randomized controlled trials.BMJ 2010; 341:C5702.

[21] Klein EA.Thompson IMJr,Tangen CM,Crowley JJ,Lucia MS, Goodman PJ, etal . Vitamin E and the risk of prostate cancer:the selenium and Vitamin E cancer prevention trial(SELECT).JAMA 2011; 306:1549-56.

[22] Sung KC,RyuS,LeeJY,Kim JY,Wild SH,Byrne CD.Effect of exercise on the development ofnew fatty liver and the resolution of existing fatty liver. J Hepatol 2016;65: 791-7.

[23] Chalasani N, Younossi ZM, Lavine AE,Charlton M, Cusi K, RinellaM, et al .The diagnosis and management of of non alcoholic fatty liver disease: practice guidance from the American Association for thestudy of Liver disease. Hepatol 2018;67: 328-57.

[24] Neuschwander –Tetri BA,Loomba R,Sanyal AJ,Lavine AE,Van Natta ML, RinellaM, Abdelmalek MF, et al. NASH Clinical Research Network. Farsenoid X nuclear receptor ligand Obeticholic acid for non cirrhotic, non alcoholic steatohepatitis(FLINT):a multicenter, randomized,placebo- controlledtrial . Lancet 2015; 385:956--65.

[25] Ratziu V,Harrison SA,Francque S,Bedossa P,Lahert P,Serfaty L, etal .GOLDEN 505 Investigator Study Group. Elafibranor,an agonist of the Peroxisome Proliferator Activated Receptor α,and δ induces resolution of non alcoholic steatohepatitis without fibrosis worsening. Gastroenterology 2016; 150:1147-59.

[26] Friedman SL, Ratziu V,Harrison SA, Abdelmalek MF, Aithal GP,Caballeria J, etal .A randomized,placebo- controlledtrial of cenicriviroc for the treatment of non alcoholic steatohepatitis with fibrosis. Hepatology 2018; 67:1754-67.

[27] Harrison SA,Bashir MR,Guy CD,Zhou R,Moylan CA,Frias JP, etal . Resmetriom(MGL-3196) for the treatment of non alcoholic steatohepatitis: multicenter ,double blinded, a randomized,placebo- controlled phase 2 trial. Lancet 2019; 394:2012--24.

[28] Ratziu V,Ladron-de-Guevara L,Safadi R,Poordad F,-Fuster F, Harrison SA, et al.The ARREST Investigator Study Group.One year results of the Global phase 2b randomized,placebo- controlled ARREST trial of aramchol,a stearoyl-Co A desaturase inhibitor,in patients with NASH . Hepatology 2018; 68:1447A-8A.

[29] Pelliciari R, Costantino G, Camioni E,Sadeghpour BM,Entrena A,Willson TM, etal . Bile acid derivatives as ligands of the Farsenoid X receptor:synthesis, evaluation and structure Activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J Med Chem 2004; 47:4559-69.

[30] Jhaveri MA,Kowdley KV.New developments in the treatment of primary biliary cholangitis:role of Obeticholic acid .Ther Clin Risk Manag 2017; 13:1053-860.

[31] Jeong SW. Non alcoholic fatty liver disease:A Drug revolution is coming . Diabetes Metab J 2020;44:640-57.

[32] Adorini L,Pruzanski M,Shapiro D. Farsenoid X receptor targeting to treat non alcoholic steatohepapititis ,Drug Discov Today 2012; 17:988-97.

[33] Pelliciari R,Fiorrucci S,Camioni E,Clerici C,Costantino G,Malony PR, etal .6Alpha-ethyl- chenodeoxycholic acid(6ECDCA),a potent and selective FXR agonist with anticholestatic activity.J Med Chem 2002; 45:3569-72.

[34] Mudaliar S,Henry RR,SanyalAJ,Morrow L,Marshall HU,Kipnes M, etal .Efficacy and safety of the Farsenoid X receptor agonist Obeticholic acid in patients withtype2 Diabetes mellitus and of non alcoholic fatty liver disease. Gastroenterology 2013; 145:574-82.

[35] Younossi ZM, Ratziu V, Loomba R,RinellaM, Anstee QM, Goodman SM, etal .REGENERATE 505 Investigator Study Group.Obeticholic acid for the treatment of non alcoholic steatohepatitis: interimanalysis from a multicenter ,double blinded , placebo- controlled phase 3 trial. Lancet 2019; 394:2184-96.

[36] Pockros PJ,Fuchs M,Freilich B,Schiff E,Kohli A, Lawitz EJ, et al. CONTROL :A a randomized, phase 2 study on Obeticholic acid and atorvastatin on lipoproteins in non alcoholic steatohepatitis.Liver Int 2019; 39:2082-93.

[37] Eaton JE,Vuppalachi R,Reddy R,Sathapathy S,Ali B,Kamath PS. Liver injury in patients with cholestatic Liver disease treated with Obeticholic acid. Hepatology 2020; 71:511-4.

[38] Tully DC,Rucker PV,Chianelli D,Williams J,Vidal A,Alper PB, etal .Discovery of Tropifexor( LIN-452),a highly potent non bile acid fxr agonist for the treatment of cholestatic Liver disease and non alcoholic steatohepatitis(NASH). J Med Chem 2017; 60:9960-73.

[39] Sanyal AJ,Lopez PM, Lawitz EJ, Kim W,Huang JF,Andreone P, etal . Tropifexor (TXR), an FXR agonist for the treatment of NASH: interim results from the first two parts of phase 2b study FLIGHT- FXR. Hepatology 2018; 68:1460A-1A.

[40] Sanyal AJ,Lopez PM, Lawitz EJ, Kim W,Huang JF,Andreone P, etal . Tropifexor, a Farsenoid X receptor agonist for the treatment of non alcoholic steatohepatitis: interim results based on baseline body mass index from the first two parts of phase 2b study . FLIGHT- FXR. J Hepatol 2019;70(ISuppl): E796-7.

[41] Trauner M,Gulamhusein A,Hameed B, Caldwell S,Shiffman ML,Landis C, etal . The nonsteroidal a Farsenoid X receptor agonist Cilofexor(GS-9674), improves markers of cholestasis and Liver injury in patients with primary sclerosing cholangitis. Hepatology 2019; 70:788-801.

[42] Lawitz EJ,Herring RJr, Younes ZH,Gane E,Ruane P,Schall RA, etal .Proof of concept studyof an apoptosis Signal regulating kinase(ASK1) inhibitor(selonosertib )in combination with an acetyl –CoA carboxylase inhibitor((GS-0976), or a Farsenoid X receptor agonist (GS-9674),in NASH. J Hepatol 2018;68(ISuppl): S57.

[43] Patel K, Harrison SA,Elkhashab M,Trotter JE, Herring R,Rojiter SE, et al. Cilofexor,A nonsteroidal a FXR agonist,in non cirrhotic patients with NASH :a phase 2 randomized controlled trial. Hepatology 2020; 72:58-71.

[44] Chianelli D ,Rucker PV,Roland J, Tully DC,Nelson J,Liu XC, etal. Nidufexor(LMB763),a novel FXR modulator for the treatment of non alcoholic steatohepatitis. J Med Chem 2020; 63:3868-80.

[45] Erstad DJ,Farrar CT,Ghoshal S.Masia R,Ferreira DS,Chen YJ, etal. Molecular magnetic resonance imagingaccurately measures the antifibrotic effect of EDP-305,a novel Farsenoid X receptor agonist. Hepatol Commun2018; 2:821-35.

[46] Ornitz DM,Itoh N.The Fibroblast growth factor signaling pathway. Wiley Interdiscip RevDev Biol2015; 4:215-66.

[47] Schaap FG,Trauner M,Jansen PL. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 2014; 11:55-67.

[48] Harrison SA, RinellaME, Abdelmalek MF, Trotter JF,Paredes AH,Arnold HL, et al. NGM282 for treatment of non alcoholic steatohepatitis:a multicenter, randomized, double blinded, placebo- controlled phase 2 trial. Lancet 2018; 391:1174-85.

[49] Harrison SA,Rossi SJ, Paredes AH, Trotter JF, Bashir MR,Guy CD, et al. NGM282 improves Liver fibrosis and histology in 12weeks in patients with non alcoholic steatohepatitis. Hepatology 2020; 71:1198-212.

[50] Cyphert HA,GeX,Kohan AB,Salati LM,Zhang Y,Hillgartner FB. Activation of the Farsenoid X receptor induces Hepatic expression and secretion of Fibroblast growth factor 21. J Biol Chem 2012;287:25123-38.

[51] Kharitonenkov A,Larsen P.FGF21 reloaded:challenges of a rapidly growing field. Trends Endocrinol Metab 2011; 22:81-6.

[52] Sonoda J,Chen MZ,Baruch A. FGF21 receptor agonists:an emerging therapeutic class for obesity –related diseases. Horm Mol Biol Clin Invest 2017; 30:20170002.

[53] Sanyal AJ,Charles ED, Neuschwander –Tetri BA,Loomba R, Abdelmalek MF, Harrison SA, et al. Pegbelfermin(MBS-986036),a Pegylated Fibroblast growth factor 21 analogue in patients with non alcoholic steatohepatitis:a , randomized, double blinded, placebo- controlled phase 2a trial. Lancet 2019; 392:2705-17.

[54] Berger J,Moller DE.The mechanisms of action of PPARs. Annu Rev Med 2002;53: 409-35.

[55] Pawlak M,Lefebvre P,Staels B. Molecular mechanisms of PPARα action and its impact on lipid metabolism , inflammation and fibrosis in non alcoholic steatohepatitis. J Hepatol 2015;62: 720-33.

[56] Francque S,Veerijken A,Caron S,Prawitt J,Paumelle R,Derudas B, etal. PPARα gene expression correlates with the severityand histological treatment response in patients with non alcoholic steatohepatitis. J Hepatol 2015;63: 164-73.

[57] Bojic LA,Huff MW. Peroxisome Proliferator Activated Receptorδ:A multifaceted metabolic player.Curr Opin Lipiodol 2013;24: 171-7.

[58] Riserus U,Sprecher D,Johnson T,Olson E,Hirschberg S,Liu A, etal. Activation of Peroxisome Proliferator Activated Receptorδ (PPAR δ) promotes reversal of multiple metabolic abnormalities ,reduces Oxidative stress,and increases fatty acid oxidation in moderately obese men. Diabetes 2008;57: 332-9.

[59] Boubia M,Poupardin O,Barth M,Binet J,Peralba P,Mounier J, etal.Design ,synthesis and evaluationof a novel series of indole sulfonamide Peroxisome Proliferator Activated Receptor (PPAR )α/γ/δ triple Activators :discovery of Lanfibranor,a new antifibrotic Clinical candidate . J Med Chem 2018; 61:2246-65.

[60] American Diabetes Association.8. Pharmacologic approaches to glycaemic treatment: Standards of medical care in Diabetes-2018. Diabetes Care 2018; 41:S73-85.

[61] Eng C,Kramer CK,Zinman B,Retnakaran R. Glucagon like peptide 1 Receptor agonist and basal insulin combination treatment for the management of type2 Diabetes:a systematic review and meta-analysis. Lancet 2014; 384:2228-34.

[62] Eguchi Y,Kitajima Y,Hyogo H,Takahashi H,Kojima M,Ono M, etal.Japan Study Group for NAFLD(JSGNAFLD),Pilot study of with Liraglutide effects in non alcoholic steatohepatitis and non alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res 2015;45: 269-78.

[63] Armstrong MJ,Houlihan DD,Rowe JA,Clausen WH,El-brond B,Gough SC, etal. Safety and efficacy of Liraglutide in patients with type2 Diabetesand elevated liver enzymes:individual patients data meta-analysis of the LEAD program. Aliment Pharmacol Ther 2013;37: 234-42.

[64] Shimizu M, Suzuki K,Kato K,Jojima T,Iijima T,MurohisaT, etal. Evaluation of the effect of Dapagliflozin,a Sodium –glucose cotransporter 2inhibitor on hepatic steatosis and fibrosis using transient elastography in patients with type2 Diabetes and non alcoholic fatty liver disease. . Diabetes Obes Metab 2019;21:285-92.

[65] Soccio RE, Chen ER,Lazar MA. Thiazolidenediones and the promise of insulin sensitization in type2 Diabetes. Cell Metab 2014;20:573-91.

[66] Chen Z,Vigueira PA,Chambers KT,Hall AM,Mitra MS,QiN, etal. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel Peroxisome Proliferator Activated Receptor γ sparing thiazolidenedione. J Biol Chem 2012;287:23537-48.

[67] McCommis KS,Hodges WT,Brunt EM,Nalbantoglu I,McDonald WG, etal.Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of non alcoholic steatohepatitis. Hepatology 2017; 65:1543-56.

[68] Colca JR, McDonald WG,Carey GS,Cole SL, Holewa DD,Brightwell –Conrad AS, etal.Identification of a mitochondrial target of thiazolidenedione insulin sensitizers(mTOT):relationship to newly Identified mitochondrial pyruvate carrier proteins.PLoS One 2013;8:e61551.

[69] Colca JR, McDonald WG,Adams WJ.MSDC-0602K,a metabolic modulator directed at the core pathology of non alcoholic steatohepatitis. Expert Opin Invest Drugs 2018; 27:631-6.

[70] Harrison SA, Alkhouri N, Davison BA, Sanyal AJ, Colca JR,Edwards C, etal. Insulin sensitizer MSDC-0602K, in non alcoholic steatohepatitis: a , randomized,double blinded , placebo- controlled phase IIb Study. J Hepatol 2020;72: 613-26.

[71] Lefebvre P, Moyle G, Reshef R,Richman LP, Thompson M, HongF, et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist in cenicriviroc in animal models of Liver and Kidney fibrosis. PLoS One 2016;11:e1158156.

[72] Friedman SL, Sanyal AJ, Goodman SM, Lefebvre E, Gottwald M,Fischer L, Ratziu V. Efficacy and safety study of cenicriviroc for treatment of non alcoholic steatohepatitis in adult subjects with Liver fibrosis:CENTAUR Phase 2b study design.Contemp Clin Trials2016; 47:356-65.

[73] Sinha RA, BruinstroopE, Singh BK, Yen PM. Non alcoholic fatty liver disease and hypercholesterolemia:role of thyroid hormones, metabolites, and agonists.Thyroid 2019;29: 1173-91.

[74] Bohinc BN, MichelottiG, Xie G, Pang H, SuzukiA, GuyCD, et al. Repair related activation of hedgehog signaling in stromal cells promotes intra hepatic hypo thyroidism. Endocrinology 2014; 155:4591-601.

[75] Loomba R, Neutel J, Mohseni R, Bernard D, Severance R, Dao M, et al. A novel Liver Receptor beta agonist, significantly reduces Liver fat with both low and high doses in patients withNon alcoholic fatty liver disease:a Phase 2 randomized, placebo- controlledtrial. J Hepatol 2019;70(1Suppl): E150-1.

[76] Lelkin –Frenkel A, Gonen A, Shaish A, Goldiner I, Lelkin –Gobbi D, Konikoff FM, et al. Fatty acids Bile acid conjugate inhibits hepatic stearoyl-Coenzyme A desaturase and is nonatherogenic. Arch Med Res 2010; 41:397-404.

[77] Abu-Elheiga L, Brinkley WR, Zhong L, Chirala SS, WoldegiorgisG, Wakil SJ. The sub cellular localization of acetyl-CoA Carboxylase 2. Proc Natl Acad Sci USA 2000;97:1444-9.

[78] Brooks SC3rd, Brooks JS, LeeWH, LeeMG, Kim SG. Therapeutic potential of dithiolethiones for hepatic diseases. Pharmacol Ther 2009;124:31-43.

[79] Winder WW, Hardie DG.AMP-activated protein kinase, a metabolic master switch:possible roles in type2 Diabetes. Am J Physiol 1999;277:E1-10.

[80] Kim W, KimBG, Lee JS, Lee CK, Yeon JE, ChangMS, et al. Randomized Clinical trial:the Efficacy and safety study ofoltipraz, a liver X Receptoralpha –inhibitory dithiolethione in in patients with Non alcoholic fatty liver disease. Aliment Pharmacol Ther 2017;45: 1073-83.

[81] Abu-Elheiga L, Jayakumar A, Baldini A, Chirala SS, WakilSJ. Human acetyl-CoA Carboxylase characterization, molecular cloning and evidence for two isoforms. Proc Natl Acad Sci USA 1995;92:4011-5.

[82] Harriman G, Greenwood J, Bhat S, Huang X, Wang R, Paul D, et al. Acetyl-CoA Carboxylase inhibition BY ND -630reduces hepatic steatosis, improves insulin sensitivity, and modulatesdyslipidaemia in rats. Proc Natl Acad Sci USA 2016;113:E1796-805.

[83] Loomba R, Kayali Z, Nurredin M, Ruance P, La M, et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients withNon alcoholic fatty liver disease. Gastroenterology 2013; 155:1463-73.

[84] Barondes SH, CastronovoV, Cooper DN, Cummings RD, Drickamer K, Feizi T, et al. Galectins: a family of animal beta-galactoside binding lectins. Cell 1994;76:597-8.

[85] Yang RY, Hsu DK, Liu FT. Expression of Galectin-3- modulates T-Cell growth and apoptosis. Proc Natl Acad Sci USA 1996;93:6737-42.

[86] Sano H, Hsu DK, Yu L, Apgar JR, Kuwabara I, Yamanaka T, et al. Human Galectin-3 is a novel chemoattractant for monocyte and macrophages. J Immunol 2000;165:2156-64.

[87] Tellez-Sanz –R, Garcia-FuentesL, Vargas Berenguel A. Human Galectin-3 selective and high affinity inhibitors. Present state and future perspectives. Curr Med Chem 2013; 20:2979-90.

[88] Harrison SA, Marri SR, Chalasani N, Kohli R, Aronstein W, ThompsonGA, et al. Randomized Clinical Study: GRMD-02, a Galectin-3inhibitor, vs placebo in patients having non alcoholic steatohepatitis with advanced fibrosis. Aliment Pharmacol Ther 2016;44: 1183-98.

[89] Chalasani N, Abdelmalek MF, Garcia-Tsao G, Vuppalanchi R, Akhouri N, RinellaM, et al. Belamectin (GRMD-02) Study Investigators. Effects of Belamectin, an inhibitor of Galectin-3, in patients with non alcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology 2020; 158:1334-45.

[90] Pedrosa M, Seyedkazemi S,Francque S, Sanyal AJ, RinellaM, et al. A Randomized, double blinded, multicenter, Phase 2b, study to evaluate the safety and Efficacy of a combination of tropifexor and cenicrviroc in patients with non alcoholic steatohepatitis andliver fibrosis: study design of the TANDEM Trial. placebo- controlled phase 3 trial. Contemp Clin Trials2020; 88:105889.



DOI: https://doi.org/10.30564/jer.v3i2.3580

Refbacks

  • There are currently no refbacks.
Copyright © 2021 Kulvinder Kochar Kaur, Gautam Allahbadia, Mandeep Singh


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.